Format

Send to

Choose Destination
Ann N Y Acad Sci. 2010 Dec;1213:62-9. doi: 10.1111/j.1749-6632.2010.05863.x.

Clostridium difficile: progress and challenges.

Author information

1
School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA. jb@jhmi.edu

Abstract

There is a surge of new interest in C. difficile infection (CDI) reflecting substantial increases in cases and fatalities. The new challenges by this now old pathogen have brought renewed interest in all facets of the disease. Particularly important are the role of fluoroquinolones as inducing agents, the new polymerase chain reaction test to detect toxigenic strains in stools, the important role of the NAP-1 strain, recent evidence favoring oral vancomycin over metronidazole in seriously ill patients, and new guidelines for management.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center